Signum Surgical

Signum Surgical is a private, commercial-stage medical device company pioneering a novel, minimally invasive treatment for anal fistula. Its lead product, the BioHealx implant, is a helical, barbed, absorbable device designed to close the fistula tract within the sphincter muscle, addressing key shortcomings of current surgical options like high recurrence and incontinence risk. The company is led by a seasoned medtech executive team with a strong track record of innovation and exits. Signum is positioned to address a significant unmet clinical need in a sizable procedural market, primarily in the United States and Europe.

A proprietary helical, barbed, absorbable implant delivered via a single-use device to achieve tissue apposition for closing fistula tracts and other soft tissue defects.

The competitive landscape includes traditional surgical techniques (fistulotomy, seton), advanced procedures like LIFT and advancement flaps, and competing devices such as biologic fistula plugs. Signum's BioHealx differentiates by using a mechanical tissue apposition mechanism that is fully absorbable and not exposed to the anal canal, aiming for a better balance of healing and continence preservation.